Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity.
Yue Zhang
No relevant relationships to disclose
Howard S. Hochster
Consultant or Advisory Role - Bayer; Boehringer Ingelheim; Genentech; Genomic Health; Sanofi
Stacey Stein
No relevant relationships to disclose
Jill Lacy
No relevant relationships to disclose